These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8664469)

  • 21. Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: a review of current UK practice.
    Codispoti M; Mankad PS
    Perfusion; 2000 Jun; 15(3):191-201. PubMed ID: 10866420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet protection in coronary artery surgery: benefits of heparin-coated circuits and high-dose aprotinin therapy.
    Wendel HP; Schulze HJ; Heller W; Hoffmeister HM
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4):388-92. PubMed ID: 10468249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose heparin versus full-dose heparin with high-dose aprotinin during cardiopulmonary bypass. A preliminary report.
    von Segesser LK; Garcia E; Turina MI
    Tex Heart Inst J; 1993; 20(1):28-32. PubMed ID: 7685221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprotinin and heparin monitoring during cardiopulmonary bypass.
    Hunt BJ; Segal H; Yacoub M
    Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current strategies for optimizing the use of cardiopulmonary bypass in neonates and infants.
    Shen I; Giacomuzzi C; Ungerleider RM
    Ann Thorac Surg; 2003 Feb; 75(2):S729-34. PubMed ID: 12607719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aprotinin and organon 10172: a successful combination for coronary artery bypass surgery complicated by heparin-induced thrombocytopenia.
    Alvarez MJ; Mezzatesta PJ
    Aust N Z J Surg; 2000 Nov; 70(11):819-21. PubMed ID: 11147447
    [No Abstract]   [Full Text] [Related]  

  • 27. Thrombin generation with heparin-bonded cardiopulmonary bypass circuits.
    Bannan S; Martin PG
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):849. PubMed ID: 8800182
    [No Abstract]   [Full Text] [Related]  

  • 28. Issues of biocompatibility: heparin-coated extracorporeal circuit.
    Hsu LC
    Int Anesthesiol Clin; 1996; 34(2):109-22. PubMed ID: 8799749
    [No Abstract]   [Full Text] [Related]  

  • 29. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children.
    Seghaye MC; Duchateau J; Grabitz RG; Jablonka K; Wenzl T; Marcus C; Messmer BJ; von Bernuth G
    Ann Thorac Surg; 1996 Apr; 61(4):1205-11. PubMed ID: 8607684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Descending thoracic aortic aneurysm repair with the aid of partial cardiopulmonary bypass: heparin-coated circuits versus nonheparin-coated circuits.
    Morishita K; Kawaharada N; Fukada J; Hachiro Y; Kurimoto Y; Fujisawa Y; Saito T; Abe T
    Artif Organs; 2005 Apr; 29(4):300-5. PubMed ID: 15787624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aprotinin dosing: how much is enough?
    Niimi KS
    J Extra Corpor Technol; 2004 Dec; 36(4):384-90. PubMed ID: 15679284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen.
    Bennett-Guerrero E; Sorohan JG; Howell ST; Ayuso L; Cardigan RA; Newman MF; Mackie IJ; Reves JG; Mythen MG
    Anesth Analg; 1996 Dec; 83(6):1189-92. PubMed ID: 8942584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conservation of blood during cardiovascular surgery.
    Cooley DA
    Am J Surg; 1995 Dec; 170(6A Suppl):53S-59S. PubMed ID: 8546249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative aprotinin: effect on blood loss and transfusion requirements in cardiac operations.
    Ciçek S; Demirkiliç U; Kuralay E; Ozal E; Tatar H
    Ann Thorac Surg; 1996 May; 61(5):1372-6. PubMed ID: 8633944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin coating with aprotinin reduces blood activation during coronary artery operations.
    Baufreton C; Jansen PG; Le Besnerais P; te Velthuis H; Thijs CM; Wildevuur CR; Loisance DY
    Ann Thorac Surg; 1997 Jan; 63(1):50-6. PubMed ID: 8993240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. More biocompatibility in cardiopulmonary bypass for high-risk patients.
    Baufreton C
    Ann Thorac Surg; 2006 Feb; 81(2):790-1; author reply 791. PubMed ID: 16427917
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of two doses of aprotinin in patients receiving aspirin before coronary bypass surgery.
    Moran SV; Lema G; Medel J; Irarrazaval MJ; Zalaquett R; Garayar B; Flaskamp R
    Perfusion; 2000 Mar; 15(2):105-10. PubMed ID: 10789564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of aprotinin during cardiopulmonary bypass in a patient with protein C deficiency.
    Sievert A; McCall M; Blackwell M; Bradley S
    J Extra Corpor Technol; 2003 Mar; 35(1):39-43. PubMed ID: 12680495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function.
    Koster A; Pasic M; Bauer M; Kuppe H; Hetzer R
    Ann Thorac Surg; 2000 Jan; 69(1):37-41. PubMed ID: 10654482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.